Juno Therapeutics (JUNO) Will Make 11 Presentations at Upcoming ASH Meeting; Includes Preclinical Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Futures extend losses after economic data
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen at multi-decade lows, dollar drops before US data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Juno Therapeutics to Highlight CAR T Advances in B-cell Malignancies at ASH 2016
November 3, 2016 9:05 AM EDT-- Updated JCAR017 NHL data to be presented
-- Analyst and Investor Event and Webcast on Monday, December 5, at 8:30 p.m. Pacific Time
SEATTLE--(BUSINESS WIRE)-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the bodys immune system to revolutionize the treatment of cancer, today announced that seven oral and four poster presentations detailing updated clinical and preclinical results generated in partnership with its collaborators will be presented at the 58th American Society of Hematology (ASH) Annual Meeting. Senior executives will also... More
